Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Study:

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Rationale:

n/a

Purpose:

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study of NP001 in subjects with ALS.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Amyotrophic Lateral Sclerosis Drug: NP001
Drug: NP001
Drug: Placebo
Phase 2

Verified by Neuraltus Pharmaceuticals, Inc. November, 2012

Sponsored by: Neuraltus Pharmaceuticals, Inc.
Information provided by: Neuraltus Pharmaceuticals, Inc.
ClinicalTrials.gov identifier: NCT01281631

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Robert G. Miller, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site